Home/Filings/4/0001209191-21-031481
4//SEC Filing

Shah Jatin 4

Accession 0001209191-21-031481

CIK 0001503802other

Filed

May 10, 8:00 PM ET

Accepted

May 11, 8:58 AM ET

Size

5.3 KB

Accession

0001209191-21-031481

Insider Transaction Report

Form 4
Period: 2021-05-07
Shah Jatin
EVP, Chief Medical Officer
Transactions
  • Purchase

    Common Stock

    2021-05-07$8.60/sh+23,250$199,992131,802 total
Footnotes (2)
  • [F1]Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $8.5850 to $8.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
  • [F2]Includes 861 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2021.

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001782186

Filing Metadata

Form type
4
Filed
May 10, 8:00 PM ET
Accepted
May 11, 8:58 AM ET
Size
5.3 KB